Please assess the completion status of the following clinical trial:

Trial Title: MGR001 / Advair Diskus Local Equivalence Study in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key inclusion criteria include:~* Male or female subjects aged ≥18 years. Females may be of either childbearing or non-childbearing potential~* Physician diagnosed history of asthma for at least 12 weeks prior to screening~* pre-bronchodilator FEV1 60-85% at screening and other specified visits~* Post-bronchodilator reversibility \>/=12%~* Non-smokers and prior smokers with no history of smoking within the past 12 months prior to screening and a total smoking history of ≤10 pack-years~* Subjects able to discontinue asthma medications for the duration of the study and be maintained using albuterol as required~* Body mass index between 18-40 kg/m2 inclusive~Key exclusion criteria include:~* Presence or recent history of any other active, severe, progressive, and/or uncontrolled clinical disease, eg, poorly controlled Type 1 or 2 diabetes, seizure disorder or epilepsy, cerebrovascular accident, significant cardiac conduction abnormalities~* Respiratory conditions other than asthma and allergic rhinitis, including but not limited to: severe nasal polyposis or chronic rhinosinusitis, chronic obstructive pulmonary disease, bronchiectasis, Churg-Strauss Disease, lung resection, pulmonary fibrosis (primary or secondary), pulmonary hypertension, cystic fibrosis, sarcoidosis~* History of life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s)~* In patient hospitalization (not including ER visits) for an asthma exacerbation within the past year or during the run in period~* An asthma exacerbation requiring change in asthma therapy or oral/IV corticosteroids in the 3 months prior to screening~* History of seasonally unstable asthma where the season will coincide with the subject's participation in the study~* Use of prescription or non-prescription drugs, including beta blockers, tricyclic antidepressants, oral decongestants, benzodiazepines, digitalis, phenothiazines, monoamine oxidase inhibitors, etc~* Suspected hypersensitivity to the study drugs (including lactose) or severe milk protein allergy~* Clinically significant abnormalities in the screening ECG~* Evidence of alcohol or drug abuse or dependency within 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MGR001 (Type: EXPERIMENTAL): MGR001 administered two times per day by inhalation throughout the study
- Advair Diskus (Type: ACTIVE_COMPARATOR): Advair Diskus administered two times per day by inhalation throughout the study
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete